Payment overview · 2025
General Payments
$712.24
45 reported records · 16 companies
Healthcare provider profile · identity verified
Annette Williams
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · IRVINE, KY · NPI 1689083784
Verified facts
What the public records show
CMS Open Payments records show Annette Williams received $712.24 in general payments during 2025 across 45 reported records.
ABBVIE INC. accounted for 24.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 22 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Nurtec Odt, Ozempic, Trelegy Ellipta, Ubrelvy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Ubrelvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 102 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Nurtec Odt by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $176.16 | 24.7% | 15 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $78.52 | 11.0% | 4 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $54.51 | 7.7% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $52.86 | 7.4% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $49.78 | 7.0% | 3 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $38.49 | 5.4% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $33.49 | 4.7% | 2 | 2025 |
| Sage Therapeutics, LLC | Unresolved — no canonical attribution shown | $32.82 | 4.6% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $32.36 | 4.5% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $30.49 | 4.3% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $30.13 | 4.2% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $29.41 | 4.1% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $22.60 | 3.2% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $17.76 | 2.5% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $16.94 | 2.4% | 1 | 2025 |
| Tonix Medicines, Inc. | Unresolved — no canonical attribution shown | $15.92 | 2.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $712.24 | 45 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $131.90 | 10 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $54.51 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $49.78 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $44.26 | 5 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $42.60 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $38.49 | 1 | 2025 |
Source payment records
|
|||||
| UZEDY Normalized: uzedy |
Drug | Teva Pharmaceuticals USA, Inc. | $35.92 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $34.73 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $33.49 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $33.49 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $33.28 | 4 | 2025 |
Source payment records
|
|||||
| ZURZUVAE Normalized: zurzuvae |
Drug | Sage Therapeutics, LLC | $32.82 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $32.36 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $30.49 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $30.13 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $29.41 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $22.60 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $18.13 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $18.13 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $17.76 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $16.94 | 1 | 2025 |
Source payment records
|
|||||
| TONMYA Normalized: tonmya |
Drug | Tonix Medicines, Inc. | $15.92 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 102 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
102 | 15 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
47 | 12 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 263 | 48 |
| Atorvastatin Calcium | Atorvastatin Calcium | 243 | 65 |
| Lisinopril | Lisinopril | 171 | 51 |
| Levothyroxine Sodium | Levothyroxine Sodium | 158 | 44 |
| Pantoprazole Sodium | Pantoprazole Sodium | 157 | 41 |
| Amlodipine Besylate | Amlodipine Besylate | 135 | 40 |
| Omeprazole | Omeprazole | 114 | 37 |
| Ozempic | Semaglutide | 102 | 15 |
| Tramadol Hcl | Tramadol Hcl | 100 | 30 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 98 | 34 |
| Montelukast Sodium | Montelukast Sodium | 92 | 18 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 91 | 25 |
| Ondansetron Odt | Ondansetron | 86 | 24 |
| Buspirone Hcl | Buspirone Hcl | 85 | 22 |
| Trazodone Hcl | Trazodone Hcl | 83 | 22 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 81 | 23 |
| Alprazolam | Alprazolam | 75 | 17 |
| Carvedilol | Carvedilol | 73 | 19 |
| Duloxetine Hcl | Duloxetine Hcl | 73 | 19 |
| Furosemide | Furosemide | 72 | 23 |
| Famotidine | Famotidine | 67 | 20 |
| Losartan Potassium | Losartan Potassium | 67 | 21 |
| Metoprolol Succinate | Metoprolol Succinate | 67 | 19 |
| Zolpidem Tartrate | Zolpidem Tartrate | 67 | 11 |
| Hydrochlorothiazide | Hydrochlorothiazide | 64 | 24 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 63 | 19 |
| Prednisone | Prednisone | 63 | 42 |
| Pregabalin | Pregabalin | 62 | 14 |
| Fluticasone Propionate | Fluticasone Propionate | 59 | 21 |
| Metformin Hcl | Metformin Hcl | 59 | 13 |
| Baclofen | Baclofen | 53 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 49 | 16 |
| Bupropion Xl | Bupropion Hcl | 49 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 48 | 14 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 47 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 47 | 39 |
| Eliquis | Apixaban | 47 | 12 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 46 | 15 |
| Temazepam | Temazepam | 45 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 44 | suppressed |
| Meloxicam | Meloxicam | 42 | 12 |
| Clonazepam | Clonazepam | 39 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 39 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 38 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 35 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 35 | suppressed |
| Potassium Chloride | Potassium Chloride | 35 | 12 |
| Diclofenac Sodium | Diclofenac Sodium | 34 | 18 |
| Diazepam | Diazepam | 33 | 11 |
| Metformin Hcl Er | Metformin Hcl | 33 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 33 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 33 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 32 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 32 | suppressed |
| Mounjaro | Tirzepatide | 32 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 31 | suppressed |
| Jardiance | Empagliflozin | 31 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 30 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 30 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 30 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 29 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 28 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 28 | suppressed |
| Estradiol | Estradiol | 27 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 26 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 26 | suppressed |
| Allopurinol | Allopurinol | 25 | suppressed |
| Glipizide Er | Glipizide | 25 | suppressed |
| Lamotrigine | Lamotrigine | 25 | suppressed |
| Methocarbamol | Methocarbamol | 25 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 23 | 22 |
| Metoprolol Tartrate | Metoprolol Tartrate | 23 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 23 | 11 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 22 | suppressed |
| Simvastatin | Simvastatin | 22 | suppressed |
| Sucralfate | Sucralfate | 22 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 21 | suppressed |
| Mirtazapine | Mirtazapine | 21 | suppressed |
| Synthroid | Levothyroxine Sodium | 21 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 20 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 20 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 20 | suppressed |
| Chlorthalidone | Chlorthalidone | 19 | suppressed |
| Linzess | Linaclotide | 19 | suppressed |
| Lorazepam | Lorazepam | 19 | suppressed |
| Novolog Flexpen | Insulin Aspart | 19 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 19 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 17 | suppressed |
| Ezetimibe | Ezetimibe | 17 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 17 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 17 | suppressed |
| Januvia | Sitagliptin Phosphate | 16 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 15 | suppressed |
| Finasteride | Finasteride | 15 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 14 | 12 |
| Nurtec Odt | Rimegepant Sulfate | 14 | suppressed |
| Spironolactone | Spironolactone | 14 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 14 | suppressed |
| Atenolol | Atenolol | 13 | suppressed |
| Dexamethasone | Dexamethasone | 13 | 11 |
| Nifedipine Er | Nifedipine | 13 | suppressed |
| Nystatin | Nystatin | 13 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 12 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 12 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 12 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 12 | suppressed |
| Ubrelvy | Ubrogepant | 12 | suppressed |
| Xarelto | Rivaroxaban | 12 | suppressed |
| Bumetanide | Bumetanide | 11 | suppressed |
| Methylprednisolone | Methylprednisolone | 11 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 11 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $712.24 · 45 records | ABBVIE INC. | AIRSUPRA, AUSTEDO XR, Auvelity, CAPLYTA, Cologuard Collection Kit, Dexcom G6 Transmitter, FANAPT, FREESTYLE LIBRE 3, NURTEC ODT, Ozempic, QULIPTA, Rybelsus, TONMYA, TRELEGY ELLIPTA, UBRELVY, UZEDY, VOQUEZNA, VRAYLAR, Veozah, Wegovy, ZAVZPRET, ZURZUVAE | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Nurtec Odt play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error